-
Superior Samples • Proven Performance
Colli-Pee® | FV-5000
Colli-Pee®: An innovative solution for non-invasive urine collection and stabilization
Colli-Pee® is a patented sampling device allowing volumetric and standardized first-void urine collection. The platform consists of variants capturing different volumes, ranging from 4 to 45 mL*. Collector tubes can be prefilled with a preservative, which enables longer storage and shipment of urine at room temperature.
How does Colli-Pee® works - watch our instruction video.
Benefits of urine sampling with Colli-Pee®
First-void urine contains higher concentrations of analytes associated with various sexually transmitted infections, including Human Papillomavirus (HPV) and Chlamydia trachomatis (CT) DNA. Additionally, first-void urine sampling is important to identify cancer biomarkers, such as prostate cancer.
Colli-Pee® is easy-to-use by both men and women and can be posted to individuals as well as labs for testing purposes, allowing for home-collection.
Read more about first-void urine collection with Colli-Pee®
Urine stability
Colli-Pee® can be prefilled with Novosanis’ UCM reagent, to allow preservation of DNA in urine. To extend the preservation coverage to other analytes (RNA, EV, cfDNA) a new preservative, UAS, is currently in development.
Read more about Novosanis' urine stabilization solutions
Volume variants
Colli-Pee® can be prefilled with Novosanis’ UCM reagent, to allow preservation of DNA in urine. To extend the preservation coverage to other analytes (RNA, EV, cfDNA) a new preservative, UAS, is currently in development.
Read more about Colli-Pee® volume variants
User Instructions : 6 Easy Steps
Full terms and conditions for all DNA Genotek products are available here.
DNA Genotek's sample collection devices and nucleic acid stabilization chemistries are protected by issued and pending patents in numerous countries around the world.
“ I am convinced that the non-invasive character of urine sampling, with option of home collection, will definitely help to enroll underserved women in cervical cancer screening and follow-up programs across the world. ”
Alex Vorsters, Ph.D.
Project Group Leader HPV VAXINFECTIO (University of Antwerp)
